Pfizer India and Max Hospitals partner to create Fellowship Programme to amplify scope of care and build new avenues of research

23-07-2022, Pfizer India has signed a MOU (Memorandum of Understanding) with Max Super Specialty Hospitals to provide Fellowships to young doctors in 17 Max Specialty Hospitals spread across 4 states of India. The goal of the Fellowships is to understand and establish drug efficacy in proven therapies by mining real world evidence from Electronic Patient Records.

The big focus of this exercise is to bolster the principal pillars of public health in India – prevention, treatment and disease management. Additionally, the two organizations also interpret this collaboration as a window to build centres of excellence (CoE) in rare diseases – featuring RWE studies, capability-building workshops and Fellowship programs.

For the Fellows, this presents a unique opportunity to pick up precious insight, recognition and funding/sponsorships. Selection parameters for the Fellows will be decided by medical and research specialists at Max Healthcare. Technical and financial support to the initiative will come from Pfizer.

For Pfizer, this is a strategic move to build a future-ready ecosystem that syncs industry and academia to lift benchmarks of medical research in the country.

Addressing the media on the occasion, Dr Sandeep Budhiraja (Group Medical Director, Max Healthcare) shared, “Real-world evidence is becoming increasingly important in healthcare decision making. It has the potential to provide invaluable insights and work in synergy with other emerging developments such as a greater use of data science and genomics. Together, these efforts can transform the way we look at modern medicine. It gives us immense pleasure to collaborate with Pfizer India, which has taken significant strides into several areas of cutting-edge research, with the aim to solve critical scientific problems.”

*This press release is published by VOH team.*